Jazz Pharmaceuticals Board Changes

On October 23, 2025, Jazz Pharmaceuticals plc announced significant changes to its board of directors. Dr. Ted Love was appointed as a Class I director, effective December 1, 2025, with his term expiring at the 2027 annual general meeting. Dr. Love will also serve on the Audit Committee and Science and Medicine Committee. Concurrently, Kenneth W. O’Keefe notified the board of his retirement, effective December 1, 2025. O’Keefe’s decision was not due to any disagreement with the company. Dr. Love will receive standard cash and equity compensation for his role.